OpenAI buys Orchestra Bio to fast-track drug discovery
OpenAI just acquired Orchestra Bio to combine agentic workflows with its Rosalind life sciences suite. The integration is designed to let AI handle coordination hiccups across complex trials and compress the grueling 10-to-15-year drug development cycle for partners like Novo Nordisk and Moderna.